Setting

North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Published: 18 Jan 2020 | Report Code: 10247334 | Pages: 105

North America human insulin market is expected to reach $23.52 billion by 2025, growing by 7.36% annually over the next years. Highlighted with 27 tables and 52 figures, this 105-page report “North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify North America human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country. Based on product type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Human Insulin Drugs • Human Insulin Delivery Devices Based on product, the North America Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand) • Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand) Based on product, the North America Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Syringes • Pens (further segmented into Disposable, Reusable, Pen needles) • Pumps • Others Based on application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Type 1 Diabetes • Type 2 Diabetes • Gestational Diabetes and Prediabetes Based on distribution channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Geographically, the following national/local markets are fully investigated: • U.S. • Canada For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players: Astra Zeneca PLC Biocon Eli Lilly Exir Julphar Novo Nordisk AS Pfizer Sanofi Aventis Sedico Wockhardt (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	5
1.1 Industry Definition and Research Scope	5
1.1.1 Industry Definition	5
1.1.2 Research Scope	6
1.2 Research Methodology	8
1.2.1 Overview of Market Research Methodology	8
1.2.2 Market Assumption	9
1.2.3 Secondary Data	9
1.2.4 Primary Data	9
1.2.5 Data Filtration and Model Design	10
1.2.6 Market Size/Share Estimation	11
1.2.7 Research Limitations	12
1.3 Executive Summary	13
2 Market Overview and Dynamics	15
2.1 Market Size and Forecast	15
2.2 Major Growth Drivers	16
2.3 Market Restraints and Challenges	19
2.4 Emerging Opportunities and Market Trends	22
2.5 Porter’s Fiver Forces Analysis	25
3 Segmentation of North America Market by Product Type	29
3.1 Market Overview by Product Type	29
3.2 Human Insulin Drugs	31
3.3 Human Insulin Delivery Devices	32
4 Segmentation of North America Human Insulin Drugs Market by Drug Product	33
4.1 Market Overview by Drug Product	33
4.2 Modern Human Insulin	35
4.2.1 Modern Human Insulin by Type	37
4.2.2 Modern Human Insulin by Brand	41
4.3 Traditional Human Insulin	48
4.3.1 Traditional Human Insulin by Type	50
4.3.2 Traditional Human Insulin by Brand	53
5 Segmentation of North America Human Insulin Delivery Devices Market by Device Product	56
5.1 Market Overview by Product	56
5.2 Syringes	58
5.3 Pens	59
5.4 Pumps	60
5.5 Other Devices	62
6 Segmentation of North America Market by Application	63
6.1 Market Overview by Application	63
6.2 Type 1 Diabetes	65
6.3 Type 2 Diabetes	66
6.4 Gestational Diabetes and Prediabetes	67
7 Segmentation of North America Market by Distribution Channel	68
7.1 Market Overview by Distribution Channel	68
7.2 Hospital Pharmacies	70
7.3 Retail Pharmacies	71
7.4 Online Pharmacies	72
8 North America Market 2019-2026 by Country	73
8.1 Overview of North America Market	73
8.2 U.S. Market	76
8.3 Canadian Market	80
9 Competitive Landscape	82
9.1 Overview of Key Vendors	82
9.2 New Product Launch, Partnership, Investment, and M&A	86
9.3 Company Profiles	88
Astra Zeneca PLC	88
Biocon	90
Eli Lilly	91
Exir	92
Julphar	93
Novo Nordisk AS	94
Pfizer	95
Sanofi Aventis	96
Sedico	97
Wockhardt	98
10 Investing in North America Market: Risk Assessment and Management	99
10.1 Risk Evaluation of North America Market	99
10.2 Critical Success Factors (CSFs)	102
Related Reports and Products	105
List Of Tables

Table 1.  Snapshot of North America Human Insulin Market, 2019-2026	14
Table 2.  Main Product Trends and Market Opportunities in North America Human Insulin Market	22
Table 3. North America Human Insulin Market by Product Type, 2019-2026, $ mn	29
Table 4. North America Human Insulin Drugs Market by Product, 2019-2026, $ mn	33
Table 5. North America Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, $ mn	36
Table 6. North America Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, $ mn	36
Table 7. North America Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, $ mn	49
Table 8. North America Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, $ mn	49
Table 9. North America Human Insulin Delivery Devices Market by Product, 2019-2026, $ mn	56
Table 10. North America Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, $ mn	59
Table 11. North America Human Insulin Market by Application, 2019-2026, $ mn	63
Table 12. North America Human Insulin Market by Distribution Channel, 2019-2026, $ mn	68
Table 13. North America Human Insulin Market by Country, 2019-2026, $ mn	74
Table 14. U.S. Human Insulin Market by Product Type, 2019-2026, $ mn	78
Table 15. U.S. Human Insulin Market by Application, 2019-2026, $ mn	78
Table 16. U.S. Human Insulin Market by Distribution Channel, 2019-2026, $ mn	78
Table 17. Canada Human Insulin Market by Product Type, 2019-2026, $ mn	81
Table 18. Canada Human Insulin Market by Application, 2019-2026, $ mn	81
Table 19. Canada Human Insulin Market by Distribution Channel, 2019-2026, $ mn	81
Table 20. North America Human Insulin Market by Key Vendor, 2019, $ mn	84
Table 21. Astra Zeneca PLC: Company Snapshot	88
Table 22. Astra Zeneca PLC: Business Segmentation	88
Table 23. Astra Zeneca PLC: Product Portfolio	89
Table 24. Astra Zeneca PLC: Revenue, 2016-2018, $ mn	89
Table 25. Astra Zeneca PLC: Recent Developments	89
Table 26.  Risk Evaluation for Investing in North America Market, 2019-2026	100
Table 27. Critical Success Factors and Key Takeaways	103
List Of Figures

Figure 1.  Research Method Flow Chart	8
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	11
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026	13
Figure 4. North America Human Insulin Market, 2019-2026, $ mn	15
Figure 5. Primary Drivers and Impact Factors of North America Human Insulin Market	16
Figure 6. Primary Restraints and Impact Factors of North America Human Insulin Market	19
Figure 7. Porter’s Fiver Forces Analysis of North America Human Insulin Market	25
Figure 8. Breakdown of North America Human Insulin Market by Product Type, 2019-2026, % of Revenue	29
Figure 9. Contribution to North America 2020-2026 Cumulative Revenue by Product Type, Value ($ mn) and Share (%)	30
Figure 10. North America Human Insulin Market: Human Insulin Drugs, 2019-2026, $ mn	31
Figure 11. North America Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, $ mn	32
Figure 12. Breakdown of North America Human Insulin Drugs Market by Product, 2019-2026, % of Revenue	33
Figure 13. Contribution to North America Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%)	34
Figure 14. North America Human Insulin Market: Modern Human Insulin, 2019-2026, $ mn	35
Figure 15. North America Modern Human Insulin Market: Long-acting, 2019-2026, $ mn	37
Figure 16. North America Modern Human Insulin Market: Rapid- acting, 2019-2026, $ mn	38
Figure 17. North America Modern Human Insulin Market: Premixed, 2019-2026, $ mn	40
Figure 18. North America Modern Human Insulin Market: Lantus, 2019-2026, $ mn	41
Figure 19. North America Modern Human Insulin Market: Apidra, 2019-2026, $ mn	42
Figure 20. North America Modern Human Insulin Market: Levemir, 2019-2026, $ mn	43
Figure 21. North America Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, $ mn	44
Figure 22. North America Modern Human Insulin Market: Novomix, 2019-2026, $ mn	45
Figure 23. North America Modern Human Insulin Market: Humalog, 2019-2026, $ mn	46
Figure 24. North America Modern Human Insulin Market: Other Brands, 2019-2026, $ mn	47
Figure 25. North America Human Insulin Market: Traditional Human Insulin, 2019-2026, $ mn	48
Figure 26. North America Traditional Human Insulin Market: Short-acting, 2019-2026, $ mn	50
Figure 27. North America Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, $ mn	51
Figure 28. North America Traditional Human Insulin Market: Premixed, 2019-2026, $ mn	52
Figure 29. North America Traditional Human Insulin Market: Humulin, 2019-2026, $ mn	53
Figure 30. North America Traditional Human Insulin Market: Insuman, 2019-2026, $ mn	54
Figure 31. North America Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, $ mn	55
Figure 32. Breakdown of North America Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue	56
Figure 33. Contribution to North America Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value ($ mn) and Share (%)	57
Figure 34. North America Human Insulin Delivery Devices Market: Syringes, 2019-2026, $ mn	58
Figure 35. North America Human Insulin Delivery Devices Market: Pens, 2019-2026, $ mn	59
Figure 36. North America Human Insulin Delivery Devices Market: Pumps, 2019-2026, $ mn	60
Figure 37. North America Human Insulin Delivery Devices Market: Other Devices, 2019-2026, $ mn	62
Figure 38. Breakdown of North America Human Insulin Market by Application, 2019-2026, % of Revenue	63
Figure 39. Contribution to North America 2020-2026 Cumulative Revenue by Application, Value ($ mn) and Share (%)	64
Figure 40. North America Human Insulin Market: Type 1 Diabetes, 2019-2026, $ mn	65
Figure 41. North America Human Insulin Market: Type 2 Diabetes, 2019-2026, $ mn	66
Figure 42. North America Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, $ mn	67
Figure 43. Breakdown of North America Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue	68
Figure 44. Contribution to North America 2020-2026 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%)	69
Figure 45. North America Human Insulin Market: Hospital Pharmacies, 2019-2026, $ mn	70
Figure 46. North America Human Insulin Market: Retail Pharmacies, 2019-2026, $ mn	71
Figure 47. North America Human Insulin Market: Online Pharmacies, 2019-2026, $ mn	72
Figure 48. Breakdown of North America Human Insulin Market by Country, 2019 and 2026, % of Revenue	74
Figure 49. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)	75
Figure 50. U.S. Human Insulin Market, 2019-2026, $ mn	77
Figure 51. Canada Human Insulin Market, 2019-2026, $ mn	80
Figure 52. Growth Stage of North America Human Insulin Industry over the Forecast Period	82

Astra Zeneca PLC	
Biocon	
Eli Lilly	
Exir	
Julphar	
Novo Nordisk AS	
Pfizer	
Sanofi Aventis	
Sedico	
Wockhardt